Johnson & Johnson ended discussions with Actelion Pharmaceuticals Ltd. regarding a potential transaction as it was not able to reach an agreement that would create adequate value for its shareholders.

Bloomberg News previously reported that Actelion rejected Johnson & Johnson's initial offer, which was priced at CHF246 per share, valuing Actelion at $26 billion.